These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
189 related items for PubMed ID: 29498910
21. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study. Okimoto N, Sakai A, Yoshioka T, Kobayashi T, Asano K, Akahoshi S, Ishikura T, Fukuhara S, Fuse Y, Mizuno T, Katae Y, Matsumoto H, Ogawa T, Nishida S, Ikeda S, Menuki K, Saito J, Okazaki Y, Mizuno N, Fujiwara S. J Bone Miner Metab; 2020 Mar; 38(2):230-239. PubMed ID: 31586241 [Abstract] [Full Text] [Related]
22. Long-term effects of amino-bisphosphonates on circulating γδ T cells. Rossini M, Adami S, Viapiana O, Fracassi E, Ortolani R, Vella A, Zanotti R, Tripi G, Idolazzi L, Gatti D. Calcif Tissue Int; 2012 Dec; 91(6):395-9. PubMed ID: 23052225 [Abstract] [Full Text] [Related]
23. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study. Shiraki M, Kuroda T, Takeuchi Y, Sugimoto T, Tanaka S, Suzuki H, Hiraishi K, Nakamura T. Calcif Tissue Int; 2021 Dec; 109(6):666-674. PubMed ID: 34247263 [Abstract] [Full Text] [Related]
24. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Wark JD, Bensen W, Recknor C, Ryabitseva O, Chiodo J, Mesenbrink P, de Villiers TJ. Osteoporos Int; 2012 Feb; 23(2):503-12. PubMed ID: 21331467 [Abstract] [Full Text] [Related]
25. Cytokines and insulin resistance after zoledronic acid-induced acute phase response. Kassi G, Papamichael K, Papaioannou G, Giagourta I, Thanou S, Triantaphyllopoulou M, Zapanti E, Papandroulaki F, Ktena V, Karga H. Immunol Invest; 2014 Feb; 43(6):544-55. PubMed ID: 24661204 [Abstract] [Full Text] [Related]
26. Role of zoledronic acid in the prevention and treatment of osteoporosis. Räkel A, Boucher A, Ste-Marie LG. Clin Interv Aging; 2011 Feb; 6():89-99. PubMed ID: 21594000 [Abstract] [Full Text] [Related]
29. The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients. Lu K, Wu YM, Shi Q, Gong YQ, Zhang T, Li C. Osteoporos Int; 2023 Sep; 34(9):1613-1623. PubMed ID: 37247006 [Abstract] [Full Text] [Related]
30. Association between vitamin D and zoledronate-induced acute-phase response fever risk in osteoporotic patients. Lu K, Shi Q, Gong YQ, Li C. Front Endocrinol (Lausanne); 2022 Sep; 13():991913. PubMed ID: 36299453 [Abstract] [Full Text] [Related]
31. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR. J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237 [Abstract] [Full Text] [Related]
32. Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis. Nakamura Y, Shimizu T, Asano T, Shimodan S, Ishizu H, Takahashi D, Takahata M, Iwasaki N. J Bone Miner Metab; 2021 Sep; 39(5):824-832. PubMed ID: 33821302 [Abstract] [Full Text] [Related]
33. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ, Muxi A, Guañabens N. Bone; 2012 Jul; 51(1):54-8. PubMed ID: 22487299 [Abstract] [Full Text] [Related]
34. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063 [Abstract] [Full Text] [Related]
35. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029 [Abstract] [Full Text] [Related]
36. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study. Zheng WB, Dai Y, Hu J, Zhao DC, Wang O, Jiang Y, Xia WB, Xing XP, Li M. Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740 [Abstract] [Full Text] [Related]
37. Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study. Du Y, Yu W, Gou H, Lei Y, Zhang T, Tang W, Chen M, Li H, Cheng Q. BMC Musculoskelet Disord; 2024 Sep 02; 25(1):694. PubMed ID: 39223504 [Abstract] [Full Text] [Related]
38. Patient preference, efficacy, and compliance with zoledronic acid for glucocorticoid-induced osteoporosis in patients with autoimmune diseases. Kim JW, Jung JY, Kim HA, Son H, Suh CH. Postgrad Med J; 2024 Apr 22; 100(1183):334-341. PubMed ID: 38297995 [Abstract] [Full Text] [Related]
39. Novel combined pharmacological strategy to alleviate acute phase response following zoledronic acid treatment. Chen CH, Yeap EK, Hsu CH, Lu YM, Cheng TL, Lee TC, Ho CJ, Li JY, Shen HY, Huang HT, Lu CC, Lin SY. Arch Osteoporos; 2024 Oct 15; 19(1):97. PubMed ID: 39404970 [Abstract] [Full Text] [Related]
40. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project]. Dalle Carbonare L, Bertoldo F, Lo Cascio V. Reumatismo; 2009 Oct 15; 61(1):54-64. PubMed ID: 19370189 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]